A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-10-20
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate
the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid
tumors .